Literature DB >> 14675867

Enumeration of latently infected CD4+ T cells from HIV-1-infected patients using an HIV-1 antigen ELISPOT assay.

Jean-Michel Fondere1, Jean-François Planas, Marie-France Huguet, Vincent Baillat, Frederic Bolos, Jacques Reynes, Jean-Pierre Vendrell.   

Abstract

BACKGROUND: Latently infected resting CD4(+) T cells carrying replication-competent HIV-1 are present in naive, chronically infected individuals as well as in those who are receiving highly active antiretroviral therapy (HAART). These cells serve as a potential source of reactivation of viral replication and remain a major obstacle for the eradication of HIV-1.
OBJECTIVES: The enzyme-linked immunospot (ELISPOT) assay was adapted to the detection and the enumeration of HIV-1 antigen-secreting cells at the single cell level. We applied this test to count latently HIV-1-infected CD4(+) T cells. STUDY
DESIGN: Latently infected CD4(+) T cells were assessed in an in vitro model of HIV-1-infected resting CD4(+) T cells as well as in eighteen HAART-treated and in four HIV-1-infected untreated patients. Enriched CD4(+) T cells were cultured with or without antibodies against CD3 and CD28 T cell receptors and with irradiated peripheral blood mononuclear cells from HIV-1 seronegative individuals. At the term of the cell culture, CD4(+) T lymphocytes were tested using the HIV-1 antigen ELISPOT assay.
RESULTS: In the experimental HIV-1 infection model, 5579+/-4190 CD4(+) T cells secreting HIV-1 antigen were enumerated after polyclonal activation. In contrast, only 15+/-6 HIV-1 immunospots were obtained from unstimulated T cells. In all patients tested, induced HIV-1 antigen-secreting cells were measured at a frequency of 55+/-108/10(6) CD4(+) T cells.
CONCLUSION: As each immunospot represents one HIV-1 antigen-secreting cell, the HIV-1 ELISPOT assay is a powerful to enumerate circulating CD4(+) T lymphocytes latently infected with HIV-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14675867     DOI: 10.1016/s1386-6532(03)00083-0

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

2.  Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individuals.

Authors:  Jean-Michel Fondere; Gael Petitjean; Marie-France Huguet; Sharon Lynn Salhi; Vincent Baillat; Anna Macura-Biegun; Pierre Becquart; Jacques Reynes; Jean-Pierre Vendrell; Anna Macura-Biegum
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

3.  HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs.

Authors:  Max von Kleist; Stephan Menz; Hartmut Stocker; Keikawus Arasteh; Christof Schütte; Wilhelm Huisinga
Journal:  PLoS One       Date:  2011-03-24       Impact factor: 3.240

4.  A stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patients.

Authors:  Jessica M Conway; Daniel Coombs
Journal:  PLoS Comput Biol       Date:  2011-04-28       Impact factor: 4.475

5.  VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies.

Authors:  Maria C Puertas; Ángel Bayón-Gil; Maria C Garcia-Guerrero; Maria Salgado; Víctor Urrea; Sara Morón-López; Ruth Peña; Esther Jiménez-Moyano; Bonaventura Clotet; Julia G Prado; Javier Martinez-Picado
Journal:  mBio       Date:  2021-06-22       Impact factor: 7.867

6.  Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients.

Authors:  Gaël Petitjean; Yassine Al Tabaa; Edouard Tuaillon; Clement Mettling; Vincent Baillat; Jacques Reynes; Michel Segondy; Jean Pierre Vendrell
Journal:  Retrovirology       Date:  2007-08-29       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.